Post-marketing oncology studies are gaining traction as a viable strategy to enhance patient recruitment and reduce operational costs in clinical trials. Traditionally, these studies have been deprioritized, particularly in community oncology centers, which often focus on more immediate research priorities. However, the increasing complexity of oncology therapies and the need for real-world evidence are prompting a shift in this perspective.
By leveraging existing patient populations and utilizing streamlined protocols, post-marketing studies can significantly accelerate recruitment timelines while minimizing expenses associated with traditional trial designs. This trend not only aligns with the regulatory push for real-world data but also addresses the growing demand for evidence-based treatment outcomes from stakeholders across the pharmaceutical landscape.
The implications for pharma B2B professionals are profound, as embracing post-marketing studies could facilitate more efficient resource allocation and enhance the overall value proposition of oncology products in a competitive market.
Start your 7-day trial and see what the database can do →
